International Liver Congress - 2013

aidsmap news from ILC 2013

• Hepatitis C treatment gap in Europe: France doing well but Italy treated fewer than one in a hundred patients in 2010

  Hepatitis C treatment
  Keith Alcorn | 28 May 2013

  France led the world in the proportion of its hepatitis C patients who received treatment in 2010, but some countries in southern and eastern Europe had treatment rates that were almost tenfold ...

• Triple therapy for hepatitis C is effective after liver transplantation, but side-effects are common

  Hepatitis C treatment
  Liz Highleyman | 16 May 2013

  Adding the approved HCV protease inhibitor telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin can increase sustained viral response rates even for difficult-to-treat liver transplant recipients, but adverse events are common, researchers ...

• Movement for global access to hepatitis C treatment building momentum

  Hepatitis C treatment
  Keith Alcorn | 09 May 2013

  Access to hepatitis C treatment in low- and middle-income countries is being restricted by the high cost of interferon and a lack of commitment to treating the disease, leading to a growing ...

• Daclatasvir + asunaprevir + BMS-791352 looks promising as interferon-free combination

  New and experimental hepatitis C treatment
  Liz Highleyman | 02 May 2013

  An all-oral regimen containing three next-generation antivirals taken for either 12 or 24 weeks produced sustained virological response in more than 90% of previously untreated genotype 1 chronic hepatitis C patients in a ...

• Compassionate access to new hepatitis C drugs an "emergency" for European patients

  New and experimental hepatitis C treatment
  Keith Alcorn | 30 April 2013

  European governments must move quickly to ensure that compassionate use arrangements are put into place to allow access to new hepatitis C drugs for people with cirrhosis, advocates and doctors said at ...

• Second-generation protease inhibitor faldaprevir cures up to 80% of hepatitis C

  New and experimental hepatitis C treatment
  Keith Alcorn | 30 April 2013

  A second-generation hepatitis C protease inhibitor, faldaprevir, cured up to 80% of previously untreated people with genotype 1 hepatitis C virus (HCV) infection when combined with pegylated interferon and ribavirin, Professor Peter Ferenci ...

• Second-generation HCV protease inhibitor simeprevir pushes triple therapy cure rate up to 80%

  New and experimental hepatitis C treatment
  Keith Alcorn | 30 April 2013

  A second-generation hepatitis C protease inhibitor, simeprevir, cured around 80% of previously untreated people with genotype 1 hepatitis C virus (HCV) infection when combined with pegylated interferon and ribavirin, Professor Michael Manns of ...

• Triple-drug HCV therapy comes with high risk of serious adverse events for people with cirrhosis

  Hepatitis C treatment
  Keith Alcorn | 30 April 2013

  Currently available triple therapies for hepatitis C carry a high risk of serious side-effects for people in the most urgent need of treatment, and these patients have only a moderate chance of being ...

• Hep C quad regimens quashed, but some components go forward

  New and experimental hepatitis C treatment
  Liz Highleyman | 29 April 2013

  A pair of four-drug interferon-based hepatitis C regimens worked well, but further study has been halted after a few patients experienced serious adverse events, according to a set of presentations last week at ...

• Daclatasvir + sofosbuvir offers hepatitis C rescue therapy after current standard of care

  New and experimental hepatitis C treatment
  Liz Highleyman | 29 April 2013

  An interferon-free regimen of daclatasvir plus sofosbuvir, with or without ribavirin, cured all previously treated hepatitis C (HCV) patients who did not respond to interferon-based triple therapy using the approved HCV protease ...

• AbbVie interferon-free combination cures over 90% of hepatitis C genotype 1

  New and experimental hepatitis C treatment
  Keith Alcorn | 26 April 2013

  A four-drug combination of direct acting antivirals developed by AbbVie cured hepatitis C infection in over 90% of participants in the AVIATOR study, without the need for the use of interferon, researchers reported ...

• Sofosbuvir + ribavirin cures most genotype 2 hepatitis C, but genotype 3 response is lower

  New and experimental hepatitis C treatment
  Liz Highleyman | 26 April 2013

  A dual oral regimen containing the hepatitis C nucleotide polymerase inhibitor sofosbuvir plus ribavirin produced high sustained virological response rates overall, but this was driven by very good response amongst people with hepatitis ...